Background {#Sec1}
==========

Thyroid carcinoma is the most common kind of malignant endocrine tumor, accounts for 1% of all human malignant tumors and 33% of the head and neck malignant tumors. Among the thyroid carcinoma, 80--85% are papillary thyroid carcinoma (PTC) \[[@CR1]\]. The incidence of cervical lymph node metastasis in PTC can reach to 40--90% \[[@CR1]\]. Cervical lymph node metastasis was the main risk factor for a higher recurrence in PTC patient \[[@CR2], [@CR3]\]. In general, the lymph node metastasis of PTC occurs in central compartment first**,** then expands to the lateral compartment \[[@CR4], [@CR5]\], but it also has the properties of skip metastasis. Therefore, a reasonable and comprehensive initial surgical treatment can decrease the recurrence rate and the reoperation complications. In this study we retrospectively analyzed the clinicopathological data of 966 PTC patients, summarized the features and the risk factors for cervical lymph node metastasis, to help making a reasonable surgical plan and achieve the best treatment effectiveness.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

The study was approved by the Ethical Committee of Shengjing Hospital of China Medical University. We enrolled the patients who underwent the initial thyroid operation in the general surgery department of Shengjing Hospital and were pathologically proved as PTC between January 2013 and December 2015. We excluded the patients with other types of thyroid malignant tumor, without central lymph node dissection (CLND), with the history of thyroid operation, or with incomplete data. There were 966 patients qualified and enrolled in this study.

Operation approach {#Sec4}
------------------

Thyroid nodules and cervical lymph nodes were assessed by ultrasound in all patients before surgery. Cervical contrast enhanced computed tomography (CT) and fine needle aspiration (FNA) were not routinely performed during this study and were only used in very few patients. The histology of the frozen sections were performed during the surgical procedures for all the tumors. For the unilateral lobe PTC, lobectomy plus isthmusectomy with ipsilateral CLND was performed; if nodule was detected in the contralateral lobe, total thyroidectomy was performed in our hospital. For the isthmus or bilateral PTC, total thyroidectomy plus bilateral CLND was performed. If lateral lymph node metastasis (LLNM) is evident on preoperative imaging exam or proved by fine needle aspiration cytology, a functional lateral lymph node dissection (LLND) would be performed.

Clinicopathological properties {#Sec5}
------------------------------

The following clinicopathological properties were studied to analyze the risk factors for the CLNM: gender, age, preoperative TSH level, unilateral/bilateral location of tumors in the lobes, the number and size of tumor, with or without extrathyroidal extension (ETE), distant metastasis, or Hashimoto's thyroiditis (HT), or US features including microcalcification, hypoechoic solid nodules, irregular shape, infiltrative margins, and intra-nodular vascularity. In addition to the above variables, the status of central lymph node was also considered as a clinicopathological property for analyzing the risk factors for the LLNM. Solitary was defined as one tumor in the thyroid, multifocality was defined as two or more tumors in the thyroid. Tumor size was defined as the maximal diameter in solitary case, and was defined as the maximal diameter of the largest tumor in the multifocality cases. ETE was defined as invading strap muscle, larynx, trachea, esophagus, recurrent laryngeal nerve, prevertebral fascia, encasing carotid artery or mediastinal vessels. TSH level was measured within one month before surgery in our hospital, and the normal range was 0.3--4.8uIU/mL. The HT patients were diagnosed with any one of the following criteria: positive for anti-thyroid peroxidase (TPO) antibody; positive for antithyroglobulin antibody; pathologic confirmation of HT \[[@CR6]\].

Statistics analysis {#Sec6}
-------------------

Software SPSS 17.0 was used for statistics analysis. Univariate analysis was performed with univariate logistic models, and variables with statistical significance in univariate analysis were further included in the multivariate logistic models. The multivariate analysis was performed with binary logistic regression analysis to assess independent risk factors for CLNM and LLNM. ROC curve was used to determine the critical value of the number of CLNM for predicting LLNM. Differences were assessed with the chi-square test for categorical variables. Measurement data such as TSH level, the average age and the average tumor size was presented as mean ± standard deviation. Statistical significance was considered when *P* \< 0.05.

Results {#Sec7}
=======

Patients' characteristics {#Sec8}
-------------------------

Among the 966 cases, including 194 men and 772 women, the average age was 45 ± 12 years old (ranging from 9 to 80 years old). The average tumor size was 1.34 ± 1.02 cm, ranging from 0.1 to 6 cm. The range of TSH value was 0.001--14.68 uIU/mL. 767 cases were unilateral PTC, among which 679 cases were solitary, 88 cases were multifocality. There were 199 bilateral PTC cases. All patients underwent CLND, CLNM was found in 367(38.0%) cases. 420 patients underwent the functional LLND, 211 cases had LLNM, including 155 cases with LLNM and CLNM simultaneously and 56 cases with skip metastasis. Among the solitary cases, LLNM occurred in 130 cases, of which 36 cases had skip metastasis. Surgical complications included: 138 cases of transient hypoparathyroidism(14.3%), 12 cases of permanent hypoparathyroidism(1.2%), 9 cases of unilateral vocal cord paralysis(0.9%), 2 cases of bilateral vocal cord paralysis(0.2%), 5 cases of postoperative hemorrhage(0.5%), and 8 cases of chylous leakage(0.8%). Postoperative radioiodine therapy was performed on 252 patients. All patients were followed up after surgery until February 2018. The median follow-up time was 40 months (range, 25--61 months). During the follow-up period, none of patients died. 15 cases (1.6%) experienced recurrence, including 12 cases with lymph node recurrence and 3 cases with thyroid recurrence. The patients with disease recurrence received an additional surgery.

Risk factors for CLNM {#Sec9}
---------------------

Univariate analysis showed that CLNM was significantly associated with age, male, tumor size, multifocality, bilateral location of tumors in the lobes, ETE and US features as intra-nodular vascularity or microcalcification (*P* \< 0.05). However, distant metastasis, HT, the TSH value and US features as hypoechoic solid nodules, irregular shape or infiltrative margins were not significantly associated with CLNM (*P* \> 0.05) (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}). The multivariate analysis showed age ≤ 45 years old, male, tumor size\> 1.0 cm, ETE and US features as microcalcification were the independent risk factors for CLNM (*P* \< 0.05) (Table [3](#Tab3){ref-type="table"}).Table 1Demographics and clinical characteristics of patients undergoing central lymph node dissectionClinicopathological propertiesCentral lymph node metastasisTotalNoYesSubjects, n96659962.0%36738.0%GenderFemale77249664.2%27635.8%Male19410353.1%9146.9%Age (years)≤352299742.4%13257.6%35--4524814658.9%10241.1%45--5527319370.7%8029.3%\> 5521616375.5%5324.5%Tumor size(cm)≤0.517814581.5%3318.5%0.5--1.036325570.2%10829.8%1.0--2.027514050.9%13549.1%\> 2.01505939.3%9160.7%Ultrasound feature MicrocalcificationNo70645965.0%24735.0%Yes26014053.8%12046.2% Hypoechoic solid nodulesNo18311261.2%7138.8%Yes78348762.2%29637.8% Irregular shapeNo63140163.5%23036.5%Yes33519859.1%13740.9% Infiltrative marginsNo25215862.7%9437.3%Yes71444161.8%27338.2% Intra-nodular vascularityNo32822869.5%10030.5%Yes63837158.2%26741.8%MultifocalityNo67943964.7%24035.3%Yes28716055.7%12744.3%BilateralNo76749164.0%27636.0%Yes19910854.3%9145.7%Extrathyroidal extensionNo75950065.9%25934.1%Yes2079947.8%10852.2%Distant metastasisNo96159862.2%36337.8%Yes5120.0%480.0%Hashimoto's thyroiditisNo60438463.6%22036.4%Yes36221559.4%14740.6%TSH value2.10 ± 1.652.13 ± 1.49Table 2Univariate analysis of risk factors for central lymph node metastasisOR95%CI*P* valueLowerUpperGender(male vs. female)1.591.162.180.004Age (years)\< 0.001^a^≤354.192.796.28\< 0.00135--452.151.443.51\< 0.00145--551.280.851.910.240\> 551Tumor size(cm)\< 0.001^a^≤0.510.5--1.01.861.202.890.0061.0--2.04.242.716.62\< 0.001\> 2.06.784.1111.18\< 0.001Ultrasound feature Microcalcification(yes vs. no)1.591.192.130.002 Hypoechoic solid nodules(yes vs. no)0.960.691.330.803 Irregular shape(yes vs. no)1.210.921.580.176 Infiltrative margins(yes vs. no)1.040.771.400.793 Intra-nodular vascularity(yes vs. no)1.641.242.180.001Multifocality(yes vs. no)1.451.101.920.009Bilateral(yes vs. no)1.501.092.060.012Extrathyroidal extension(yes vs. no)2.111.542.88\< 0.001Distant metastasis(yes vs. no)6.590.7359.190.092Hashimoto's thyroiditis(yes vs. no)1.190.911.560.195TSH value1.010.931.100.799^a^ means the global *p*-valuesTable 3Multivariate analysis of risk factors for central lymph node metastasisOR95%CI*P* valueLowerUpperGender(male vs. female)1.481.042.110.028Age (years)\< 0.001^a^≤354.833.117.48\< 0.00135--452.621.704.04\< 0.00145--551.500.972.320.066\> 551Tumor size(cm)\< 0.001^a^≤0.510.5--1.01.550.982.460.0601.0--2.03.222.005.18\< 0.001\> 2.04.852.818.35\< 0.001Microcalcification(yes vs. no)1.431.041.970.029Intra-nodular vascularity(yes vs. no)1.300.951.780.100Multifocality(yes vs. no)0.960.591.590.886Bilateral(yes vs. no)1.390.802.410.242Extrathyroidal extension(yes vs. no)1.681.182.390.004^a^ means the global *p*-values

Risk factors for LLNM {#Sec10}
---------------------

In 420 patients who underwent LLND, we analyzed the risk factors for LLNM. The univariate analysis showed that LLNM was statistically significant associated with age, tumor size, ETE and CLNM (*P* \< 0.05). LLNM was not significantly related with gender, US features, tumor number, unilateral or bilateral location of tumors, distant metastasis, HT, or the TSH value (*P* \> 0.05) (Tables [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}). We found that there was a significant difference in incidence of LLNM between PTC with and without CLNM. In order to further study the relationship between the number of CLNM and the incidence of LLNM, we made ROC curve to determine the critical value of the number of CLNM for predicting LLNM in 234 cases with CLNM. As shown in Fig. [1](#Fig1){ref-type="fig"}, the cutoff value of the number of CLNM was 2.5 (Sensitivity = 0.535, Specificity = 0.722, AUC = 0.669, *P* \< 0.05). Therefore we grouped the number of CLNM as: none, 1--3 and \> 3 in all models for LLNM. In the multivariate analysis, we found that only CLNM was the risk factor for LLNM, and with the increase of the number of CLNM, the OR value increased, the OR value of the number of CLNM\> 3(OR = 9.27) was more than 3 times that of the number of CLNM equal to 1--3(OR = 2.96), which suggested that the risk of LLNM increased significantly with the increase of the number of CLNM (*P \<* 0.05) (Table [6](#Tab6){ref-type="table"}).Table 4Demographics and clinical characteristics of patients undergoing lateral lymph node dissectionClinicopathological propertiesLateral lymph node metastasisTotalNoYesSubjects, n42020949.8%21150.2%GenderFemale32917252.3%15747.7%Male913740.7%5459.3%Age (years)≤351214839.7%7360.3%35--451045250.0%5250.0%45--551085651.9%5248.1%\> 55875360.9%3439.1%Tumor size(cm)≤0.5352468.6%1131.4%0.5--1.01378259.9%5540.1%1.0--2.01476946.9%7853.1%\> 2.01013433.7%6766.3%Ultrasound feature MicrocalcificationNo27714452.0%13348.0%Yes1436545.5%7854.5% Hypoechoic solid nodulesNo733345.2%4054.8%Yes34717650.7%17149.3% Irregular shapeNo25913150.6%12849.4%Yes1617848.4%8351.6% Infiltrative marginsNo954850.5%4749.5%Yes32516149.5%16450.5% Intra-nodular vascularityNo1145750.0%5750.0%Yes30615249.7%15450.3%MultifocalityNo27214252.2%13047.8%Yes1486745.3%8154.7%BilateralNo31516351.7%15248.3%Yes1054643.8%5956.2%Extrathyroidal extensionNo28615353.5%13346.5%Yes1345641.8%7858.2%Distant metastasisNo41620749.8%20950.2%Yes4250.0%250.0%Hashimoto's thyroiditisNo25113051.8%12148.2%Yes1697946.7%9053.3%The number of CLNM018613069.9%5630.1%1--3\> 316569681141.2%15.9%975858.8%84.1%TSH value2.20 ± 1.662.16 ± 1.44Table 5Univariate analysis of risk factors for lateral lymph node metastasisOR95%CI*P* valueLowerUpperGender(male vs. female)1.601.002.560.051Age (years)0.025^a^≤352.371.354.170.00335--451.560.882.780.13245--551.450.822.570.206\> 551Tumor size(cm)\< 0.001^a^≤0.510.5--1.01.460.663.230.3461.0--2.02.471.135.400.024\> 2.04.301.899.810.001Ultrasound feature Microcalcification(yes vs. no)1.300.871.950.205 Hypoechoic solid nodules(yes vs. no)0.800.481.330.392 Irregular shape(yes vs. no)1.090.741.610.671 Infiltrative margins(yes vs. no)1.040.661.640.865 Intra-nodular vascularity(yes vs. no)1.010.661.560.953Multifocality(yes vs. no)1.320.881.970.175Bilateral(yes vs. no)1.380.882.150.160Extrathyroidal extension(yes vs. no)1.601.062.430.026Distant metastasis(yes vs. no)0.991.387.100.992Hashimoto's thyroiditis(yes vs. no)1.220.831.810.311The number of CLNM\< 0.001^a^011--33.312.135.15\< 0.001\> 312.245.9825.06\< 0.001TSH value0.980.861.110.711^a^means the global *p*-values; *CLNM* central lymph node metastasisFig. 1Receiver operating characteristic curve analysis of the number of central lymph node metastasis for predicting lateral lymph node metastasis. The results of ROC showed that the cutoff value of the number of central lymph node metastasis was 2.5, which was the optimal point to distinguish between PTC with and without lateral lymph node metastasis. At this value, the sensitivity was 53.5% and the specificity was 72.2%; AUC was 0.669, and the 95% CI was 0.599--0.739Table 6Multivariate analysis of risk factors for lateral lymph node metastasisOR95%CI*P* valueLowerUpperAge (years)0.447^a^≤351.640.873.090.12535--451.260.662.400.47845--551.460.782.750.236\> 551Tumor size(cm)0.060^a^≤0.510.5--1.01.0--2.01.571.940.670.843.634.510.2970.121\> 2.03.031.247.440.015Extrathyroidal extension(yes vs. no)1.260.782.020.350The number of CLNM\< 0.001^a^011--32.961.874.70\< 0.001\> 39.274.3819.63\< 0.001^a^ means the global *p*-values; *CLNM* central lymph node metastasis

The features of the LLNM {#Sec11}
------------------------

In 211 cases with LLNM confirmed by pathology, the metastasis rates of level III (66.8%) and IV (67.3%) were significantly higher than that of level II (42.2%) and V (21.3%) (*P* \< 0.05), but the difference between level III and IV was not statistically significant (*P* \> 0.05). So, LLNM most likely occurs in level III and IV (Table [7](#Tab7){ref-type="table"}). Moreover, lymph metastasis often involved multiple levels in the lateral compartment, multiple level lymph node metastasis was found in 129 (61.1%) cases (4 levels in 18 cases, 3 levels in 40 cases and 2 levels in 71 cases). Single level lymph node metastasis in lateral compartment occurred in 82 (38.9%) cases (12 cases in level II, 31 cases in level III, 35 cases in level IV and 4 cases in level V).Table 7The incidence of lateral lymph node metastasis in different sites of lateral cervical compartmentThe sites of lateral\
compartmentLateral lymph node metastasisPositive rate*χ* ^*2*^*P* valueNoyes123. 60\< 0.001Level II1228942.2%\< 0.001^a^, \< 0.001^b^, 0.918^c^Level III7014166.8%\< 0.001^d^, \< 0.001^e^, \< 0.001^f^Level IV6914267.3%Level V1664521.3%^a^Level II vs. Level III, ^b^Level II vs. Level IV, ^c^Level III vs.Level IV, ^d^Level II vs. Level V,^e^ Level III vs. Level V, ^f^Level IV vs. Level V

To determine whether the location of the tumor is related to the occurrence of LLNM, we analyzed LLNM in 272 patients with solitary tumor who underwent LLND. We found that tumor located in the upper 1/3 of the lobe had the highest LLNM incidence (60%) (*P* \< 0.05) (Table [8](#Tab8){ref-type="table"}). To determine whether the location of the tumor was related to the level in lateral compartment of lymph node metastasis, 130 cases of solitary tumor with lateral lymph node metastasis were analyzed. We found that the location of the tumor was not related to the level in lateral compartment of lymph node metastasis (*P* \> 0.05) (Table [9](#Tab9){ref-type="table"}).Table 8Analysis about the tumor location and lateral lymph node metastasisTumor locationlateral lymph node metastasisPositive rate*χ* ^*2*^*P* valueNoYes11.4230.022Upper 1/3 of the lobe385760.0%Middle 1/3 of the lobe342037.0%Lower 1/3 of the lobe472938.2%Isthmus141348.1%Whole9115.5%Table 9Relation between tumor location and the sites of lateral lymph node metastasisTumor locationThe site of lateral lymph node metastasis*χ* ^*2*^*P* valueLevel IILevel IIILevel IVLevel V9.6210.649Upper 1/3 of the lobe (*n* = 57 cases)34383615Middle 1/3 of the lobe (*n* = 20 cases)510185Lower 1/3 of the lobe (*n* = 29 cases)816195Isthmus (*n* = 13 cases)38102Whole (*n* = 11 cases)47102

We also found that in 130 cases of solitary tumor with LLNM, 36 cases did not have CLNM, that is the so-called "skip metastasis", which have negative ipsilateral CLNM and positive ipsilateral LLNM. Further analysis found that tumors located in upper 1/3 of the lobe had the highest skip metastasis incidence (*P* \< 0.05), however, the location of the tumor was not related to the level in lateral compartment of skip metastasis (Tables [10](#Tab10){ref-type="table"}, [11](#Tab11){ref-type="table"}).Table 10Analysis between the tumor location and skip metastasisTumor locationSkip metastasisMetastasis rate*χ* ^*2*^*P* valueNoYes11.1240.021Upper 1/3 of the lobe352238.6%Middle 1/3 of the lobe18210.0%Lower 1/3 of the lobe21827.6%Isthmus9430.8%Whole1100%Table 11Relation between tumor location and the sites of skip metastasisTumor locationThe site of skip metastasis*χ* ^*2*^*P* valueLevel IILevel IIILevel IVLevel V6.6890.674Upper 1/3 of the lobe (*n* = 22 cases)1510113Middle 1/3 of the lobe (n = 2 cases)1121Lower 1/3 of the lobe (*n* = 8 cases)1242Isthmus (*n* = 4 cases)1131

Discussion {#Sec12}
==========

Although PTC is the most common pathological type of thyroid carcinoma with a 10-year survival exceeding 90% \[[@CR7]\], previous studies found that cervical lymph node metastasis was common for PTCs and 40--90% of all PTCs could occur cervical lymph node metastasis \[[@CR1], [@CR8]--[@CR10]\]. It is widely accepted that cervical lymph node metastasis is a major cause of the local recurrence of PTC and it may also influence patients' survival \[[@CR11]--[@CR13]\]. Study showed reoperation for PTC recurrence was relatively difficult and might significantly increase the surgical complications which would affect patient's quality of life \[[@CR14]\]. So, the treatment of cervical lymph nodes during initial operation is very important for the prognosis of patients. At present, there is still controversy about whether prophylactic CLND and the extent of therapeutic LLND. The main reasons for the controversy are as follows: first, CLND has potential higher incidence of complications and uncertainty of improved outcome; second, there is no evidence for what extent of LLND is the most appropriate for the management of LLNM. Therefore, for guiding cervical lymph node dissection, it is of great significance to explore the properties and risk factors of cervical lymph node metastasis in PTC patients.

Risk factors for CLNM {#Sec13}
---------------------

Same with some of the previous results, in our study male was a risk factor for CLNM \[[@CR15]--[@CR19]\], which suggested that CLNM had a gender tendency. In males patients, physical examination and imaging evaluation of cervical lymph node status should be emphasized preoperatively. Whether age is related to CLNM, the current findings are not consistent. Liu et al \[[@CR20]\] found that CLNM were not correlated with age, while other studies reported that age \< 45 years old was a risk factor for CLNM \[[@CR17]--[@CR19]\]. In this study, we found that younger age was associated with a higher odds ratio of CLNM, and age ≤ 45 years old was independent risk factor for CLNM, which suggested that CLNM should be noticed in the younger patients.

In this study, we found that microcalcification on the US image was a risk factor for CLNM. Microcalcification is a calcium salt deposition due to hyperplasis of blood vessels and fibrous, reflecting rapid growth of cancer cells. Therefore, if microcalcification is found in the nodules, the lymph node status in central region should be assessed more carefully \[[@CR21]\].

Multifocality, bilateral tumor and ETE were already included in previous studies as clinicopathological characteristics, there were studies showing that multifocality, bilateral tumor and ETE were the risk factors for CLNM \[[@CR17], [@CR22]--[@CR24]\], but our study showed that ETE was the risk factor for CLNM, which may be due to that once the tumor cells invade the thyroid capsule, it is easy to transfer to the surrounding lymph nodes along the rich lymphatic tissue around the capsule.

Tumor size was always considered as an important predictive factor for cervical lymph node metastasis in PTC, but the cutoffs were different. Ahn et al \[[@CR18]\] showed that tumor size≥1 cm was the risk factor for CLNM, while Yan et al \[[@CR17]\] considered that tumor size≥0.25 cm. Furthermore, some studies reported that cervical lymph node metastasis was positively related to the primary tumor's size, as the size of the tumor increased, the incidence of cervical lymph node metastasis increased \[[@CR17], [@CR19], [@CR25]\]. Our study divided the tumor size into 4 groups based on the AJCC staging system and the definition of PTMC. The multivariate analysis showed that the larger tumor was associated with an increased odds of CLNM, and tumor size\> 1.0 cm was the independent risk factor for CLNM. So we considered that the tumor size\> 1.0 cm was threshold for CLNM.

Features and risk factors for LLNM {#Sec14}
----------------------------------

There were many studies about the features and the risk factors for LLNM, but few of them had comprehensive clinicopathological properties, and the results of those studies were controversy. Zhang et al \[[@CR16]\] reported that ETE, bilateral tumor and CLNM were risk factors for LLNM. Niel et al \[[@CR26]\] considered that tumor located in upper pole, CLNM, and tumor size\> 1.5 cm were the risk factors for LLNM, but Lin et al \[[@CR19]\] considered that CLNM wasn't risk factor for LLNM. In this study, we found that only CLNM was the independent risk factor for LLNM; and the OR value increased with the increase of the number of CLNM, the OR value of the number of CLNM\> 3(OR = 9.27) was more than 3 times that of the number of CLNM equal to 1--3 (OR = 2.96) (*P \<* 0.05), which suggested that CLNM number \> 3 was much more prone to LLNM than CLNM number equal to 1--3. So when the number of CLNM\> 3, the LLND should be more actively performed.

To date, the extent of therapeutic lateral neck dissection for PTC remains unclear. Several authors have reported that PTC metastasis is generally present at level II to V in lateral compartment, and lateral neck dissection including levels II to V is necessary for complete clearance of lateral neck metastasis \[[@CR27]--[@CR29]\]. But some authors raise objections to routine level V dissection for PTC patients with lateral compartment lymph node metastasis \[[@CR30], [@CR31]\]. In our study, lymph node metastasis in the lateral compartment occurred mostly in level III and IV, and multiple levels involvement was common. Our data consistent with the idea that extent of lateral central neck dissection should include levels II, III, IV and V.

In most of the previous studies, the solitary tumor location was divided into 4 groups as the upper 1/3, middle 1/3, lower 1/3 and isthmus, the relationship between tumor location and LLNM was examined \[[@CR16], [@CR32], [@CR33]\]. Zhang et al \[[@CR16]\] demonstrated that the primary tumor in the upper 1/3 of the lobe had a lower risk for CLNM and a higher risk for LLNM. Qubain et al \[[@CR33]\] showed that tumor in the upper 1/3 of the lobe was more vulnerable to transfer to lymph node in the upper cervical region, and the tumor in the isthmus and the lower 1/3 of the lobe was more likely to transfer to lymph node in the lower cervical region. Furthermore, it has been found that the skip metastasis of LLNM often happens in tumor located in the upper 1/3 of the lobe \[[@CR16], [@CR34]\]. Lei et al \[[@CR34]\] reported that 39 patients with lymph node skip metastasis in their study had a much higher rate of level II but a lower rate of Level III, IV and V lymph node involvement. In our study, the solitary tumor location was divided into 5 groups as the upper1/3, middle1/3, lower1/3, isthmus and whole which means tumor occupying the whole lobe. We found that among the 272 solitary tumor patients who underwent LLND, tumor located in the upper 1/3 of the lobe had the highest incidence of LLNM. Furthermore, by analyzing 130 solitary tumor cases with LLNM, we found skip metastasis was more vulnerable to occur in tumor located in upper 1/3 of the lobe, which might be due to the upper 1/3 lymphatic vessels of the lobe draining into the deep lateral lymph nodes, which are in common carotid artery bifurcation along the superior thyroid artery and vein. However, we didn't find that the location of the tumor was related to the level in lateral compartment of lymph node metastasis and skip metastasis in our study, which may be due to the small sample of solitary tumor with LLNM and skip metastasis, further investigation should be done by expanding the sample.

In this study, the positive rate of metastasis was not high in patients who underwent lateral neck dissection, only 50.3%. The possible reason for this is that we assessed lymph node metastasis primarily by ultrasound, contrast enhanced CT and FNA were only used in very few patients during the study. The sensitivity and specificity of ultrasound in assessing cervical lymph node metastasis is not high, and the results of ultrasound depends on the operator's diagnostic experience to a large extent, which leads to a low positive rate of lateral neck dissection performed according to ultrasound. To solve this problem, we now routinely perform cervical contrast enhanced CT, ultrasound-suspected metastatic lymph nodes are further assessed by FNA, which can reduce unnecessary LLND. The combination of the US/CT/FNA/intraoperative biopsy could achieve a very high sensitivity and specificity in assessing cervical lymph node metastasis.

Conclusions {#Sec15}
===========

In summary, we considered that prophylactic CLND should be performed in patients with risk factors as male, age ≤ 45 years old, tumor size\> 1 cm, and ETE and US features as microcalcification. LLND should be more actively performed in patients with the number of CLNM\> 3. Extent of LLND should include levels II, III, IV and V. Lymph nodes status should be preoperatively assessed by US, CT and FNA. For tumor located in the upper 1/3 of the lobe, LLNM and skip metastasis was likely occurred, so lateral lymph node should be noticed when lymph node status was preoperatively evaluated by imaging examination.
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